277 related articles for article (PubMed ID: 29856031)
1. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
Vachey G; Déglon N
Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
[TBL] [Abstract][Full Text] [Related]
2. CRISPR takes on Huntington's disease.
Eisenstein M
Nature; 2018 May; 557(7707):S42-S43. PubMed ID: 29844549
[No Abstract] [Full Text] [Related]
3. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
Cambon K; Déglon N
Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
[TBL] [Abstract][Full Text] [Related]
4. Production and Validation of Lentiviral Vectors for CRISPR/Cas9 Delivery.
Ryø LB; Thomsen EA; Mikkelsen JG
Methods Mol Biol; 2019; 1961():93-109. PubMed ID: 30912042
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Monteys AM; Ebanks SA; Keiser MS; Davidson BL
Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
[TBL] [Abstract][Full Text] [Related]
6. Gene Disruption Using CRISPR-Cas9 Technology.
Hu N; Malek SN
Methods Mol Biol; 2019; 1881():201-209. PubMed ID: 30350208
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 as a tool to dissect cancer mutations.
Sayed S; Paszkowski-Rogacz M; Schmitt LT; Buchholz F
Methods; 2019 Jul; 164-165():36-48. PubMed ID: 31078796
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage.
Sun J; Carlson-Stevermer J; Das U; Shen M; Delenclos M; Snead AM; Koo SY; Wang L; Qiao D; Loi J; Petersen AJ; Stockton M; Bhattacharyya A; Jones MV; Zhao X; McLean PJ; Sproul AA; Saha K; Roy S
Nat Commun; 2019 Jan; 10(1):53. PubMed ID: 30604771
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of Human AMPK Using the CRISPR/Cas9 Genome-Editing System.
Grenier A; Sujobert P; Olivier S; Guermouche H; Mondésir J; Kosmider O; Viollet B; Tamburini J
Methods Mol Biol; 2018; 1732():171-194. PubMed ID: 29480475
[TBL] [Abstract][Full Text] [Related]
11. Design and Assembly of CRISPR/Cas9 Lentiviral and rAAV Vectors for Targeted Genome Editing.
Sandoval IM; Collier TJ; Manfredsson FP
Methods Mol Biol; 2019; 1937():29-45. PubMed ID: 30706388
[TBL] [Abstract][Full Text] [Related]
12. Huntington disease: Selective deactivation of Huntington disease mutant allele by CRISPR-Cas9 gene editing.
Malkki H
Nat Rev Neurol; 2016 Nov; 12(11):614-615. PubMed ID: 27686048
[No Abstract] [Full Text] [Related]
13. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
[TBL] [Abstract][Full Text] [Related]
14. Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology.
Qiu Y; Ding Q
STAR Protoc; 2021 Mar; 2(1):100307. PubMed ID: 33554142
[TBL] [Abstract][Full Text] [Related]
15. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
17. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
18. Genome Editing: CRISPR-Cas9.
Hoof JB; Nødvig CS; Mortensen UH
Methods Mol Biol; 2018; 1775():119-132. PubMed ID: 29876814
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 for Mutagenesis in Rice.
Char SN; Li R; Yang B
Methods Mol Biol; 2019; 1864():279-293. PubMed ID: 30415343
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
Alkanli SS; Alkanli N; Ay A; Albeniz I
Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
